PALO ALTO, Calif., July 28 /PRNewswire/ -- Affymax, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering are being sold by Affymax.
The underwriters of the offering will be Morgan Stanley & Co. Incorporated as sole book runner and co-lead manager, Cowen and Company, LLC and Thomas Weisel Partners LLC as co-lead managers, and RBC Capital Markets as co- manager. The number of shares to be offered and the price range for the offering have not yet been determined.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick, New York, NY 10014, telephone 866-718-1649.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Affymax, Inc.
Affymax, Inc. is a clinical-stage biopharmaceutical company creating novel peptide-based drugs to improve the treatment of serious and often life- threatening conditions. Affymax’s lead product candidate, Hematide(TM), is currently in Phase 2 clinical trials for the treatment of anemia associated with chronic kidney disease and cancer.
Affymax, Inc.
CONTACT: Corporate Contact, Mary Fermi, Senior Director, CommercialDevelopment of Affymax, Inc., +1-650-812-8722; or Media Contact, JaniBergan of WeissComm Partners, +1-415-946-1064, orjbergan@weisscommpartners.com, for Affymax, Inc.
Web site: http://www.affymax.com/
